stoxline Quote Chart Rank Option Currency Glossary
Arcutis Biotherapeutics, Inc. (ARQT)
2.035  -0.205 (-9.15%)    12-05 16:00
Open: 2.23
High: 2.23
Volume: 2,328,277
Pre. Close: 2.24
Low: 2
Market Cap: 192(M)
Technical analysis
2023-12-05 4:18:29 PM
Short term     
Mid term     
Targets 6-month :  2.64 1-year :  3
Resists First :  2.26 Second :  2.56
Pivot price 2
Supports First :  1.75 Second :  1.46
MAs MA(5) :  2 MA(20) :  2.03
MA(100) :  5.79 MA(250) :  10.04
MACD MACD :  -0.3 Signal :  -0.4
%K %D K(14,3) :  57.1 D(3) :  42
RSI RSI(14): 41.1
52-week High :  18.04 Low :  1.75
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ARQT ] has closed below upper band by 43.8%. Bollinger Bands are 81.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.28 - 2.29 2.29 - 2.3
Low: 1.97 - 1.98 1.98 - 1.99
Close: 2.22 - 2.24 2.24 - 2.25
Company Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Headline News

Thu, 30 Nov 2023
Is Arcutis Biotherapeutics Inc (ARQT) Stock a Bad Value Thursday? - InvestorsObserver

Mon, 27 Nov 2023
Arcutis Biotherapeutics Inc (ARQT) Stock Falls -4.90% This Week: Is It a Good Pick? - InvestorsObserver

Fri, 17 Nov 2023
Should You Buy Arcutis Biotherapeutics Inc (ARQT) Stock on Friday? - InvestorsObserver

Fri, 17 Nov 2023
After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT) - Yahoo Finance

Mon, 13 Nov 2023
Should You Hold Arcutis Biotherapeutics Inc (ARQT) Stock Monday? - InvestorsObserver

Sun, 05 Nov 2023
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 94 (M)
Held by Insiders 6.895e+007 (%)
Held by Institutions 3 (%)
Shares Short 14,060 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.4687e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -96.9 %
Return on Assets (ttm) -38.8 %
Return on Equity (ttm) -168.8 %
Qtrly Rev. Growth 5 %
Gross Profit (p.s.) 175.73
Sales Per Share 5.51011e+007
EBITDA (p.s.) 3.29214e+006
Qtrly Earnings Growth -4.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -262 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales 0
Price to Cash Flow 2.41
Stock Dividends
Dividend 0
Forward Dividend 1.751e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android